45
Participants
Start Date
May 8, 2017
Primary Completion Date
July 7, 2021
Study Completion Date
December 7, 2025
Autologous genetically modified AFPᶜ³³²T cells
Infusion of autologous genetically modified AFPᶜ³³²T cells
University of Maryland, Greenebaum Cancer Center, Baltimore
Winship Cancer Institute - Emory University, Atlanta
University Hospital of Navarra, Pamplona
University of Miami, Miami
Mayo Clinic Clinical Trial Referral Office, Rochester
Washington University - School of Medicine, St Louis
MD Anderson Cancer Center, Houston
Mayo Clinic Arizona, Phoenix
USC/Norris Comprehensive Cancer Center, Los Angeles
UCLA, Los Angeles
Fred Hutchinson Cancer Research Centre, Seattle
SCCA Immunotherapy Trials Intake, Seattle
Massachusetts General Hospital, Boston
Paoli Calmettes Institute, Marseille
Centre Eugène Marquis, Rennes
Institute Gustave Roussy, Villejuif
Beatson West of Scotland Cancer Centre, Glasgow
University Hospital of Barcelona, Barcelona
Guy's Hospital, London
NIHR UCLH Clinical Research, London
The Christie NHS Foundation Trust, Manchester
Lead Sponsor
Adaptimmune
INDUSTRY